152 related articles for article (PubMed ID: 33875622)
1. Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy.
Ahn S; Lee JC; Kim J; Kim YH; Yoon YS; Han HS; Kim H; Hwang JH
Gut Liver; 2022 Jan; 16(1):129-137. PubMed ID: 33875622
[TBL] [Abstract][Full Text] [Related]
2. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
Kim SS; Ko AH; Nakakura EK; Wang ZJ; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Kim GE
Am J Surg Pathol; 2019 Mar; 43(3):334-340. PubMed ID: 30211728
[TBL] [Abstract][Full Text] [Related]
4. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
5. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.
Chen HY; Feng LL; Li M; Ju HQ; Ding Y; Lan M; Song SM; Han WD; Yu L; Wei MB; Pang XL; He F; Liu S; Zheng J; Ma Y; Lin CY; Lan P; Huang MJ; Zou YF; Yang ZL; Wang T; Lang JY; Orangio GR; Poylin V; Ajani JA; Wang WH; Wan XB
Oncologist; 2021 May; 26(5):e780-e793. PubMed ID: 33543577
[TBL] [Abstract][Full Text] [Related]
6. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach.
Chou A; Ahadi M; Arena J; Sioson L; Sheen A; Fuchs TL; Pavlakis N; Clarke S; Kneebone A; Hruby G; Sahni S; Mittal A; Samra J; Gill AJ
Am J Surg Pathol; 2021 Mar; 45(3):394-404. PubMed ID: 33074853
[TBL] [Abstract][Full Text] [Related]
7. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
Wanebo HJ; Glicksman AS; Vezeridis MP; Clark J; Tibbetts L; Koness RJ; Levy A
Arch Surg; 2000 Jan; 135(1):81-7; discussion 88. PubMed ID: 10636353
[TBL] [Abstract][Full Text] [Related]
8. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
9. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
[TBL] [Abstract][Full Text] [Related]
11. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
12. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
[TBL] [Abstract][Full Text] [Related]
14. Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications.
Nagaria TS; Wang H; Chatterjee D; Wang H
Arch Pathol Lab Med; 2020 Jul; 144(7):838-845. PubMed ID: 32023088
[TBL] [Abstract][Full Text] [Related]
15. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
16. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy.
Sohn AJ; Taherian M; Katz MHG; Prakash LR; Chatterjee D; Wang H; Kim M; Tzeng CD; Lee JE; Ikoma N; Rashid A; Wolff RA; Zhao D; Koay EJ; Sun R; Maitra A; Wang H
Am J Surg Pathol; 2023 Apr; 47(4):421-430. PubMed ID: 36746143
[TBL] [Abstract][Full Text] [Related]
17. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy.
Maeda S; Moore AM; Yohanathan L; Hata T; Truty MJ; Smoot RL; Cleary SP; Nagorney DM; Grotz TE; Park EJ; Girgis MD; Reber HA; Motoi F; Masuda T; Unno M; Kendrick ML; Donahue TR
Surgery; 2020 May; 167(5):803-811. PubMed ID: 31992444
[TBL] [Abstract][Full Text] [Related]
18. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
19. Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer.
Nicolais LM; Caron M; Verdini N; Fitzgerald TL
Am Surg; 2023 Sep; 89(9):3778-3783. PubMed ID: 37227766
[TBL] [Abstract][Full Text] [Related]
20. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
